NAD+ is involved in cellular metabolism, which makes it a legitimate subject of aging research. However, biological importance does not establish that increasing a blood measurement through a supplement or infusion improves every aspect of health.
Oral nicotinamide mononucleotide, or NMN, oral nicotinamide riboside, or NR, and intravenous NAD+ are different interventions. Evidence for one should not be used to sell another as though the route, product and outcomes were interchangeable.
What is being proposed?
NMN and NR are studied as precursors used in pathways that produce NAD+. A trial demonstrating a rise in blood NAD+ establishes a biochemical effect, not automatically a change in symptoms, organ function or survival.
Ask for the precise ingredient, formulation and route. An oral capsule, an injection and an infusion have different exposure and safety questions. A package combining them with several other products makes attribution even more difficult.
There is no reason to assume that a commercial NAD measurement provides a universally validated anti-aging target. Ask how the test is interpreted and what clinical decision follows a low or high result.
What have human NMN studies found?
A 2024 randomised study in older adults found increased blood NAD-related measures and differences in selected secondary walking and sleep outcomes. Its primary stepping-test outcome did not differ significantly between groups.
That distinction matters. A headline describing improved walking or sleep does not communicate that the primary outcome was negative. Secondary findings can guide further research, but they are not proof of broadly improved healthspan.
The trial was short and involved a selected population, with industry affiliations disclosed by the authors. These features do not invalidate it; they are reasons to look for independent replication and longer-term outcomes before making stronger claims.
Does raising NAD+ demonstrate better cognition?
In a randomised pilot trial involving older adults with mild cognitive impairment, NR increased blood NAD+ but did not improve the cognitive measures studied. Exploratory findings, including epigenetic measures, did not establish prevention of dementia.
A biomarker and a patient-important outcome can therefore move differently. A favorable-looking aging-clock result should not be presented as equivalent to improved memory or additional years of healthy life.
Ask whether the evidence concerns people with a particular condition or generally healthy adults. A research result should not be extended to every person reporting fatigue or wanting more energy.
Why do infusions need a separate safety discussion?
Infusions add requirements for product quality, sterility, administration and the management of adverse reactions. Evidence about an oral precursor does not resolve those issues or establish an effective intravenous treatment for aging.
A January 2026 FDA warning to a specific US compounder documented excessive bacterial endotoxins in a NAD+ product after patients developed serious symptoms. This was a particular product-quality failure, not proof that every NAD+ preparation has the same contamination.
Before any proposed infusion, ask who manufactures and releases the product, which quality checks apply, who administers it and what emergency arrangements exist. Product purity and clinical effectiveness are separate questions; meeting one does not prove the other.
How should a longevity claim be evaluated?
Request the study that matches the actual product, route and goal. Check whether the endpoint was a laboratory result, a functional measure, a diagnosed condition or survival. The human studies discussed here do not establish life extension.
Short-term tolerability is also not a guarantee of long-term safety in every population. Significant medical conditions, pregnancy, cancer treatment and other medicines deserve an individual review rather than reassurance based only on the compound occurring naturally in the body.
Consider the alternative use of time and resources. Addressing an identified sleep disorder, nutritional problem or cardiovascular risk should not be delayed to complete an unproven infusion package.
Questions before deciding
What outcome can reasonably be expected?
Ask for a specific, supported answer rather than language about cellular renewal or total-body optimization.
How is the product regulated where it will be used?
Request product-specific, jurisdiction-specific information. A US regulatory example does not establish Spanish or Swiss authorization.
Does SENSES offer NAD+ infusions or precursor supplements?
This article is educational and does not establish availability or endorsement. The individual proposal confirms actual services; no standard NAD regimen is implied.
Explore biological-age testing and supplement evidence.
Do newer NR trials show the same result in every condition?
No. A July 2026 pilot trial examined NR in adults with amnestic mild cognitive impairment. Forty-two participants completed twelve weeks. Blood NAD+ increased, but the study did not show improvement in its primary cognitive outcome, total cerebral blood flow or blood pressure. Exploratory regional blood-flow findings remained questions for further research.
That result adds to the distinction between changing a biochemical measurement and demonstrating a cognitive benefit. It does not establish that every possible dose, duration or population has been tested, but it does not support presenting the studied approach as an established memory treatment either.
A different 2024 randomised trial in 90 people with peripheral artery disease reported improved six-minute walking distance with NR compared with placebo after six months. Adding resveratrol did not provide additional benefit in that study. The investigators called for a larger confirmatory trial.
This is a relevant functional signal in a specific disease population. It cannot be transferred automatically to healthy adults, to cognition or to intravenous NAD+. The balanced conclusion is that human research has produced different results for different questions, while a general life-extension claim remains unsupported by these trials.
How can you evaluate a NAD testing-and-treatment package?
Ask the provider to separate three propositions: the test measures something reliably, the result identifies a clinically important problem, and the proposed intervention improves that problem. Evidence for the first proposition alone does not establish the other two.
A hypothetical package might offer a blood NAD measurement followed by a supplement intended to raise it. A higher repeat value could demonstrate an effect on the measured pathway, but the decision still needs an explanation of the expected symptom, functional or clinical benefit. Reaching a proprietary target is not automatically a patient-important outcome.
Request the actual study behind the proposed route and formulation. An oral-precursor trial does not establish the correct infusion procedure or the benefit of bypassing oral administration. Faster delivery into the circulation is a pharmacological difference, not proof of a better long-term result.
Keep the practical burden in view. Repeated appointments, blood tests, infusion access and the cost of continuing treatment should have a clear purpose. Ask what would lead the clinician to recommend not proceeding or to stop an ineffective intervention rather than simply escalating the package.
Review the original concern independently. Persistent fatigue, new cognitive symptoms or difficulty walking may need an established diagnostic pathway. A commercial NAD result should not narrow that assessment prematurely. Our fatigue guide and brain-health guide explain broader questions.
Frequently asked questions about NAD+, NMN and NR
Are NMN and NR interchangeable because both relate to NAD+?
No. They are different compounds, and evidence should match the actual formulation and use. A shared biological pathway does not establish equivalent absorption, clinical effects or safety. Ask whether the cited human trial used the same substance and route as the product being proposed.
Does an increase in blood NAD+ prove that every organ has rejuvenated?
No. A blood measurement does not directly establish a beneficial change in every tissue, nor does it demonstrate improved function or survival. The cognitive trials illustrate why the biochemical and clinical questions need separate answers. Avoid interpreting a large percentage rise as an equally large improvement in health.
Is an infusion more effective because it avoids digestion?
That claim needs direct evidence for the proposed indication and route. Bypassing digestion changes administration and introduces its own safety and product-quality requirements. It does not make results from oral studies applicable by default. Our infusion guide explains why route and indication need separate scrutiny.
Can resveratrol or another supplement be added to amplify the effect?
Do not assume that combining plausible mechanisms produces an additive benefit. The peripheral-artery-disease trial did not find an added benefit from resveratrol in its studied setting. Other combinations need their own evidence and safety review. A stack assembled from separate studies is not the same as a tested intervention.
Does short-term tolerability establish long-term safety?
No. Small or short studies can miss uncommon events and do not cover every medical circumstance. Ask who was excluded from the study and how closely they resemble you. A compound’s natural presence in the body does not by itself establish the safety of concentrated supplementation or an infusion.
Should I buy a NAD test before seeing a clinician about low energy?
A clinician should first help define the problem and decide which assessment is useful. A proprietary measurement may not answer the cause of fatigue or change care. Bring symptoms, current medicines and existing results rather than assuming one metabolic marker supplies a complete diagnosis.
How should a positive study influence a decision?
Consider the population, comparison, outcome and size of the observed benefit, together with uncertainty and harms. A promising trial can justify more research or a specialist discussion without establishing routine treatment for everyone. The appropriate conclusion should be no broader than the evidence that supports it.
What should happen if symptoms arise during an infusion?
The administering clinical service needs an immediate response plan and appropriate emergency capability. Do not accept reassurance that significant symptoms are an expected sign of detoxification or rapid repair. Report what happens promptly and seek urgent help when warranted. This article does not provide instructions for managing an infusion reaction yourself.
What can SENSES responsibly explain about these products?
It can provide educational context and clarify that a study or article is not a service commitment. Any proposed clinical intervention must be confirmed separately with its indication, qualified provider and follow-up. The existence of a longevity-science library should never be treated as endorsement of every product discussed in it.
Evidence and sources
- Randomised NMN trial in older adults, 2024
- Randomised NR pilot trial in mild cognitive impairment
- FDA: Product-specific NAD+ compounding warning, January 2026
General educational information. Research findings are not a dosing recommendation, proof of life extension or confirmation of SENSES treatment availability.